Protalix BioTherapeutics, Inc. Quarterly Common Stock, Shares Authorized from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Protalix BioTherapeutics, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q2 2010 to Q2 2024.
  • Protalix BioTherapeutics, Inc. Common Stock, Shares Authorized for the quarter ending June 30, 2024 was 185M shares, a 28.5% increase year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 185M +41M +28.5% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 185M +41M +28.5% Mar 31, 2024 10-Q 2024-05-10
Q4 2023 185M +41M +28.5% Dec 31, 2023 10-Q 2024-08-14
Q3 2023 185M +41M +28.5% Sep 30, 2023 10-Q 2023-11-06
Q2 2023 144M 0 0% Jun 30, 2023 10-Q 2023-08-07
Q1 2023 144M +24M +20% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 144M +24M +20% Dec 31, 2022 10-K 2024-03-14
Q3 2022 144M +24M +20% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 144M +24M +20% Jun 30, 2022 10-Q 2023-08-07
Q1 2022 120M 0 0% Mar 31, 2022 10-Q 2023-05-04
Q4 2021 120M 0 0% Dec 31, 2021 10-K 2023-02-27
Q3 2021 120M 0 0% Sep 30, 2021 10-Q 2022-11-14
Q2 2021 120M 0 0% Jun 30, 2021 10-Q 2022-08-15
Q1 2021 120M 0 0% Mar 31, 2021 10-Q 2022-05-16
Q4 2020 120M 0 0% Dec 31, 2020 10-K 2022-03-31
Q3 2020 120M -230M -65.7% Sep 30, 2020 10-Q 2021-11-15
Q2 2020 120M -230M -65.7% Jun 30, 2020 10-Q 2021-08-16
Q1 2020 120M -130M -52% Mar 31, 2020 10-Q 2021-05-14
Q4 2019 120M +95M +380% Dec 31, 2019 10-K 2021-03-30
Q3 2019 350M +100M +40% Sep 30, 2019 10-Q 2020-10-29
Q2 2019 350M +100M +40% Jun 30, 2019 10-Q 2020-08-10
Q1 2019 250M 0 0% Mar 31, 2019 10-Q 2019-05-06
Q4 2018 25M -225M -90% Dec 31, 2018 10-K 2020-03-12
Q3 2018 250M 0 0% Sep 30, 2018 10-Q 2019-11-07
Q2 2018 250M 0 0% Jun 30, 2018 10-Q 2019-08-08
Q1 2018 250M 0 0% Mar 31, 2018 10-Q 2019-05-06
Q4 2017 250M 0 0% Dec 31, 2017 10-K 2019-03-18
Q3 2017 250M 0 0% Sep 30, 2017 10-Q/A 2019-03-18
Q2 2017 250M +100M +66.7% Jun 30, 2017 10-Q/A 2019-03-18
Q1 2017 250M +100M +66.7% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 250M +100M +66.7% Dec 31, 2016 10-K 2018-03-06
Q3 2016 250M +100M +66.7% Sep 30, 2016 10-Q 2017-11-08
Q2 2016 150M 0 0% Jun 30, 2016 10-Q 2017-08-09
Q1 2016 150M 0 0% Mar 31, 2016 10-Q 2017-05-10
Q4 2015 150M 0 0% Dec 31, 2015 10-K 2017-03-16
Q3 2015 150M 0 0% Sep 30, 2015 10-Q 2016-11-09
Q2 2015 150M 0 0% Jun 30, 2015 10-Q 2016-08-08
Q1 2015 150M 0 0% Mar 31, 2015 10-Q 2016-05-09
Q4 2014 150M 0 0% Dec 31, 2014 10-K 2016-03-08
Q3 2014 150M 0 0% Sep 30, 2014 10-Q 2015-11-09
Q2 2014 150M 0 0% Jun 30, 2014 10-Q 2015-08-10
Q1 2014 150M 0 0% Mar 31, 2014 10-Q 2016-05-09
Q4 2013 150M 0 0% Dec 31, 2013 10-K 2015-03-12
Q3 2013 150M 0 0% Sep 30, 2013 10-Q 2014-11-10
Q2 2013 150M 0 0% Jun 30, 2013 10-Q 2014-08-07
Q1 2013 150M 0 0% Mar 31, 2013 10-Q 2014-05-08
Q4 2012 150M 0 0% Dec 31, 2012 10-K 2014-03-13
Q3 2012 150M 0 0% Sep 30, 2012 10-Q 2013-11-07
Q2 2012 150M 0 0% Jun 30, 2012 10-Q 2013-08-08
Q1 2012 150M 0 0% Mar 31, 2012 10-Q 2013-05-09
Q4 2011 150M 0 0% Dec 31, 2011 10-K 2013-02-28
Q3 2011 150M 0 0% Sep 30, 2011 10-Q 2012-11-07
Q2 2011 150M 0 0% Jun 30, 2011 10-Q 2012-08-03
Q1 2011 150M Mar 31, 2011 10-Q 2012-05-09
Q4 2010 150M Dec 31, 2010 10-K 2012-02-27
Q3 2010 150M Sep 30, 2010 10-Q 2011-11-07
Q2 2010 150M Jun 30, 2010 10-Q 2011-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.